1 / 44

Drugs in dyslipidaemias

Drugs in dyslipidaemias. Dr Sanjeewani Fonseka Department of Pharmacolgy. Atheroma Focal disease of intima Deposition of C in arterial wall. Atheromatous disease myocardial infarction Cerebo vascular accidents. chy remnant. chy. Cleared by liver. TAG. Exo. FFA. FFA. Lipids.

luna
Download Presentation

Drugs in dyslipidaemias

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drugs in dyslipidaemias Dr Sanjeewani Fonseka Department of Pharmacolgy

  2. Atheroma • Focal disease of intima • Deposition of C in arterial wall

  3. Atheromatous disease • myocardial infarction • Cerebo vascular accidents

  4. chy remnant chy Cleared by liver TAG Exo FFA FFA Lipids Skeletal, cardiac and adipose tissue Endo Liver - bile (+ cholesterol) Synthesized by liver VLDL LDL Cell membrane HDL

  5. Dyslipidaemias • Hypercholesterolaemia • Hypertriglyceridaemia • Mixed dyslipidaemia

  6. Dyslipidaemias Primary • Genetically • Cassify according to lipoprotein particle Secondary • DM • Alcohol • Nephrotic • CRF • Hypothyroidism • Liver disease • Drugs

  7. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  8. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  9. Statins • Competitive inhibition of HMG CoA reductase • HMG Co A HMG Co A mevalonic acid reductase • Reduced C in the liver • ↑ Expression of LDL receptor • Increased LDL clearance

  10. Activation of sterol regulatory element binding protein 2 (SREBP2) ↑ Expression of gene encoding LDL receptor

  11. statin cont; Other effects of statins • Improve endothelial function • Decreased coagulation • Decreased inflammation • Improved stability of atherosclerotic plaques

  12. statin cont; • Well absorbed • Metabolized in liver • Extensive pre- systemic metabolism

  13. statin cont; Statins • ↓ LDL-cholesterol by 25-55% • ↑ HDL-cholesterol by 5% • ↓ triglycerides by 10-35% • Given once daily (nocte)

  14. statin cont; Statins • Lovastatin • Pravastatin • Simvastatin • Fluvastatin • Atorvastatin • Rosuvastatin

  15. statin cont; Clinical use • Primary prevention • Secondary prevention

  16. statin cont; Statins: adverse effects • Hepatotoxicity • Myotoxicity • Dyspepsia, abdominal pain, diarrhoea • Angioedema

  17. statin cont; Statins: hepatotoxicity • Asymptomatic • ↑ ALT, AST • First 6 months • Discontinued if ALT / AST > 3 times the upper limit of normal range

  18. statin cont; Statins: myotoxicity • Pain / tenderness, weakness • ↑ CK > 10 times upper limit of normal • Reversible • ↑ risk with concurrent fibrate therapy, hypothyroidism, renal insufficiency

  19. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  20. Fibrates • Activate peroxisome proliferator-activated receptor-α (PPARα) • Heterodimer binds to peroxisome proliferator response elements (PPREs) in the promoter regions of specific genes

  21. Fibrates cont

  22. Fibrates cont: • Gemfibrozil, fenofibrate • ↓ LDL-cholesterol by 5-20% • ↑ HDL-cholesterol by 10-35% • ↓ triglycerides by 20-50%

  23. Fibrates cont Clinical use • Mixed dyslipidaemia • Low HDL

  24. Fibrates cont • Well absorbed • Elimination renal

  25. Fibrates cont Fibrates: adverse effects • Gastrointestinal discomfort • Myopathy • ↑ liver transaminases • Gallstone formation (Gemfibrozil) • Displace warfarin from albumin binding sites

  26. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  27. Bile acid binding resins • Cationic polymer resins that bind non-covalently to negatively-charged bile acids in small intestine • Enterohepatic circulation of bile acids interrupted causing up-regulation of 7α-hydroxylase in hepatocytes

  28. Bile acid binding resins cont;

  29. Bile acid binding resins cont • Increased expression of the LDL receptor • Concurrent up-regulation of hepatic cholesterol and triglyceride synthesis

  30. Bile acid binding resins cont • Cholestyramine, colestipol • ↓ LDL-cholesterol by 15-30% • ↑ HDL-cholesterol by 3-5% • Triglycerides: no effect or ↑

  31. Bile acid binding resins cont • Not absorbed from GIT • Bloating & dyspepsia • Decreased absorption of digoxin, warfarin, fat-soluble vitamins • Take one hour before or 4 h after colestyramine

  32. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  33. Niacin • Also known as nicotinic acid • ↓ LDL-cholesterol by 5 – 25% • ↑ HDL-cholesterol 15 – 35% • ↓ Triglycerides by 20 – 50%

  34. Niacin cont; • ↓ adipocyte hormone-sensitive lipase activity • ↓ availability of FFA to liver for TG (VLDL) synthesis • ↑ half-life of apoA-I (major apolipoprotein in HDL)

  35. Niacin cont; adverse effects • Cutaneous flushing & pruritus • Release of prostaglandins D2 & E2 • Prevented by aspirin • Extended-release formulations associated with less flushing • hyperuricaemia, impaired insulin sensitivity, myopathy

  36. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  37. Inhibitors of cholesterol absorption • Ezetimibe • Decreases cholesterol transport from micelles into enterocytes by inhibiting brush border protein NPC1L1 • Reduces cholesterol incorporation into VLDL in liver

  38. Inhibitors of cholesterol absorption • rapidly absorbed by enterocytes • Eliminated in bile • Undergoes enterohepatic circulation • Clinical benefit uncertain

  39. Drugs in dyslipidaemias • Statins • Fibrates • Bile acid binding resins • Niacin • Inhibitors of cholesterol absorption • Omega-3 fatty acids

  40. Omega-3 fatty acids • Eicosapentaenoic acid (EPA) • Docosahexaenoic acid (DHA)

  41. Reduce triglycerides • Increase C • Benefit - uncertain

  42. Summary • Most important hyperlipidaemia is hypercholesterolaemia • Most effective drug – statin • Drugs reduce risk of MI

More Related